Aligos Therapeutics (NASDAQ:ALGS) Now Covered by HC Wainwright

HC Wainwright began coverage on shares of Aligos Therapeutics (NASDAQ:ALGS) in a research report released on Monday, MarketBeat Ratings reports. The firm issued a buy rating and a $75.00 price target on the stock.

Aligos Therapeutics Price Performance

NASDAQ ALGS opened at $13.75 on Monday. The stock’s 50 day simple moving average is $12.14 and its 200-day simple moving average is $17.20. The company has a market cap of $1.07 billion, a PE ratio of -10.74 and a beta of 2.18. Aligos Therapeutics has a 1-year low of $8.70 and a 1-year high of $30.00.

Aligos Therapeutics (NASDAQ:ALGS) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of ($4.00) by $4.75. Aligos Therapeutics had a negative return on equity of 144.16% and a negative net margin of 783.72%. The company had revenue of $1.06 million for the quarter. During the same quarter in the previous year, the business posted ($10.75) EPS. On average, equities research analysts anticipate that Aligos Therapeutics will post -0.73 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Acadian Asset Management LLC grew its holdings in shares of Aligos Therapeutics by 17.6% in the first quarter. Acadian Asset Management LLC now owns 657,995 shares of the company’s stock valued at $644,000 after purchasing an additional 98,628 shares during the period. Opaleye Management Inc. boosted its holdings in Aligos Therapeutics by 25.7% in the 1st quarter. Opaleye Management Inc. now owns 1,630,000 shares of the company’s stock valued at $1,597,000 after purchasing an additional 333,000 shares during the last quarter. Armistice Capital LLC grew its stake in shares of Aligos Therapeutics by 5.3% in the 2nd quarter. Armistice Capital LLC now owns 7,256,410 shares of the company’s stock valued at $2,540,000 after buying an additional 363,000 shares during the period. Finally, Altitude Crest Partners Inc. acquired a new stake in shares of Aligos Therapeutics during the 4th quarter worth approximately $1,889,000. 60.43% of the stock is owned by hedge funds and other institutional investors.

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).